Japan is a leader in stem cell and regenerative medicine research, and in particular in clinical translation toward the bedside. Induced pluripotent stem cell (IPSC)-based investigational therapies are rightly an area of focus in Japan given their invention by Nobel Laureate Shinya Yamanaka. Small clinical studies based on IPSC have been initiated there for several […]
Japan stem cell clinical studies rapidly piling up Read More »
Who are the top stem cell and regenerative medicine influencers to follow on Twitter and elsewhere in 2019? Terrapin asked this kind of broad question to some within our community about 5 years ago and came up with a Top 50 list of stem cell influencers, which I like to joke I was “at the top
50 stem cell influencers on Twitter to follow in 2019 Read More »
By Jeanne Loring What can you do with cells that live forever and can make every cell type in the body? The answer is: remarkable things, as new reports of clinical trials using cell types derived from pluripotent stem cells indicate. Pluripotent stem cells are either derived from embryos donated from IVF procedures (human embryonic
Autologous or Allogeneic: a stem cell question (guest post from Jeanne Loring) Read More »
In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples starting with Fate Therapeutics. Fate Therapeutics Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf
Stem cell & regenerative medicine good news including Fate Therapeutics Read More »
Each year I make a list of stem cell predictions for the following year and I’ll release my predictions for 2019 soon, but first I’m grading how my 20 predictions for 2018 turned out. It seems I did better than usual predicting what would happen this year. I only got a couple partial credit or
Good final grades on my 20 x 2018 stem cell predictions Read More »
Every year in December I go out onto a limb and make stem cell predictions for the coming year as I did in late 2017 for this year. Then usually around the 1/2-way point through the year I check in on how the predictions are faring so far at that point. In this post I give
Midterm grades on my 20 x 2018 stem cell predictions Read More »
Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work
Japan conditionally approves new IPS cell-based heart study Read More »
Do stem cells for vision loss offer real hope? I believe so, but it’s a long road and must be done right. A new paper in this area generated some buzz on top of an earlier recent pub (mentioned in this post) just a week or so ago about the potential of stem cells for vision
Perspectives on new stem cells for vision loss paper Read More »
A team of researchers at RIKEN and Kobe City Medical Center reported at a press conference today a serious adverse event in a clinical trial participant receiving an induced pluripotent stem cell (IPS cell)-based therapy for vision loss. According to Japan Times and Yahoo! Japan (in Japanese), the patient in question in the IPS cell
Adverse event in IPS cell (ips細胞) trial for vision loss in Japan: initial perspectives Read More »
Every year I look into my stem cell crystal ball and make predictions for our field including regenerative medicine. Well, I don’t really look into a crystal ball, but I try to use a combination of what I’m hearing through the grapevine, stuff I’m reading, some info that is not yet in the public domain,
20 predictions for stem cells & regenerative medicine in 2018 Read More »